Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco ... has recently been initiated (outside of the US). The open-label, first-in-human, dose escalation study will ...

It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name. The two companies said the transaction ...

Bayer pharma chief sees no big acquisitions in near future January 14, 2025 Leaders Bayern Munich should have scored several more goals in their 1-0 Bundesliga win at Borussia Moenchengladbach on ...

Bayer’s deal with Genpact opens up new ground for pharma’s use of artificial intelligence ... as with last month’s collaboration between Orbita and a US hospital. The FDA has placed the ...

Despite restructuring efforts, Bayer's financial outlook for 2025 remains ... Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

2025--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple ...

and President of Bayer’s Pharmaceuticals Division. "Our new operating model is visibly becoming a key enabler to drive growth and efficiency gains." Topline improved and poised for future growth Bayer ...